Story
OpenAI to Provide 100,000 Researchers with Free Access to Frontier AI Models

Summary
The AI company has launched a new program, part of a $250 million commitment, that will grant academics access to its most advanced models, including GPT-5.6 Sol Pro, to accelerate scientific research.
OpenAI announced on Wednesday a new initiative to provide 100,000 academic researchers with complimentary access to its most advanced artificial intelligence models. The program, called ChatGPT for Academic Researchers, aims to support scientific research and discovery by making the company's frontier technology more widely available within the academic community.
Program Details and Scope
The initiative will roll out in phases, beginning with 10,000 researchers this summer and expanding to the full 100,000 by 2027, according to the company's statement. Participants will gain access to OpenAI's frontier models, including the newly announced GPT-5.6 Sol Pro.
Key features of the program include:
- Collaboration: Each selected researcher can invite up to four collaborators from their institution.
- Data Privacy: Workspaces will feature business-grade privacy and security protections.
- Model Training: User data will not be used to train OpenAI's models by default.
Access is already being provided at institutions such as the Institute for Advanced Study and École normale supérieure. The program is open to qualifying researchers at recognized, degree-granting universities with high levels of research activity.
A Strategic Investment in Science
AdThis program is part of a broader commitment by OpenAI to invest more than $250 million through 2027 to support external scientific endeavors. This funding also supports other projects, including NextGenAI, a $50 million initiative for research institutions, and a partnership with the Department of Energy’s Genesis Mission to deploy AI in national laboratories.
The move highlights the increasing integration of AI in academic work. OpenAI reported that approximately 1.3 million people already use ChatGPT for advanced science and mathematics each week. The number of academic papers on the preprint server arXiv acknowledging ChatGPT's contribution rose from 14 in February to 100 in the first three weeks of July.
Access to Enhanced Capabilities
Researchers in the program will have access to the GPT-5.6 family of models, which demonstrate significant performance gains on scientific benchmarks. According to OpenAI, GPT-5.6 Sol achieves an 83% score on FrontierMath Tier 4, a test for research-level mathematical reasoning, compared to 72.5% for the prior GPT-5.5 model.
On the GeneBench Pro benchmark, which assesses complex biological data analysis, GPT-5.6 Sol Pro reportedly solves 31.5% of tasks. To support the effective use of these tools, OpenAI will also offer specialized training and access to experts familiar with research workflows.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.

Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.